Werner Meier

Research interests

Publications

• Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30142-x

• Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30142-x

• A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1808424

• Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

  British Journal of Cancer · 2018 · https://doi.org/10.1038/s41416-018-0271-y

• Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20.

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.35.15_suppl.5501

• Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30376-x

• Adjuvant Therapy in Lymph Node–Positive Vulvar Cancer: The AGO-CaRE-1 Study

  JNCI Journal of the National Cancer Institute · 2015 · https://doi.org/10.1093/jnci/dju426

• Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00366-6

• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70228-1

• Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group

  European Journal of Cancer · 2013 · https://doi.org/10.1016/j.ejca.2013.01.035

• Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1105535

• The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds203

• Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)

  Gynecologic Oncology · 2007 · https://doi.org/10.1016/j.ygyno.2007.02.026

• Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens

  Journal of Clinical Oncology · 2006 · https://doi.org/10.1200/jco.2005.03.2938

• Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

  JNCI Journal of the National Cancer Institute · 2006 · https://doi.org/10.1093/jnci/djj296

• 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)

  Annals of Oncology · 2005 · https://doi.org/10.1093/annonc/mdi961

• CYFRA 21-1: A new marker in lung cancer

  Cancer · 1993 · https://doi.org/10.1002/1097-0142(19930801)72:3<707::aid-cncr2820720313>3.0.co;2-x

Current projects

No projects listed.